Sensorion

Sensorion is a French clinical-stage biotechnology company focused on restoring, treating and preventing inner-ear hearing loss. It was founded in 2009 in Montpellier, France, and is listed on Euronext Paris under the ticker ALSEN. The company's pipeline combines gene therapy approaches and small-molecule drug candidates aimed at sensorineural hearing loss, sudden sensorineural hearing loss, and monogenic forms of deafness. Its lead gene therapy program, SENS-501, targets OTOF-mediated deafness, while its small-molecule candidate SENS-401 (Arazasetron) is being developed for sudden sensorineural hearing loss and for the prevention of cisplatin-induced ototoxicity. Sensorion has established partnerships with academic and clinical institutions, including a collaboration with the Institut Pasteur and the Necker-Enfants Malades Hospital in Paris, and has received support from Bpifrance. The company operates in France and conducts clinical trials in Europe and the United States. As a publicly traded biotech, Sensorion is not controlled by a single parent company; its ownership is dispersed among institutional and retail investors.

Sensorion was founded in 2009 in Montpellier, France, as a spin-off from the Institut des Neurosciences de Montpellier. The company initially focused on developing small-molecule drugs for hearing disorders. In 2014, it completed an initial public offering on Euronext Paris, raising funds to advance its pipeline. In 2018, Sensorion acquired the gene therapy assets of the French company GenSight Biologics, expanding its focus into gene therapy for hearing loss. The company has since advanced SENS-401 into clinical trials for sudden sensorineural hearing loss and cisplatin-induced ototoxicity, and has initiated preclinical and clinical development of SENS-501 for OTOF-mediated deafness. Sensorion has also entered research collaborations with the Institut Pasteur and Necker-Enfants Malades Hospital. In 2021, the company received a €10 million loan from Bpifrance to support its gene therapy programs. As of 2024, Sensorion continues to conduct clinical trials and is listed on Euronext Paris.

• 2021

  Received €10 million loan from Bpifrance

• 2018

  Acquired gene therapy assets from GenSight Biologics

• 2014

  Initial public offering on Euronext Paris

• 2009

  Founded in Montpellier, France

Clinical-stage biotech specializing in inner-ear hearing disorders, combining gene therapy and small molecules.

• SENS-501

  Gene therapy for OTOF-mediated deafness

• SENS-401 (Arazasetron)

  Small molecule for sudden sensorineural hearing loss and cisplatin-induced ototoxicity

• 2021.02.15

  Reported2021.02.15

  Sensorion adds GJB2 gene therapy target to development portfolio[2]Sensorion 将 GJB2 基因治疗靶点纳入开发组合finanznachrichten.de

  Sensorion announced the addition of GJB2, its third gene therapy candidate to emerge from its R&D collaboration with Institut Pasteur, to its development portfolio.

• 2020.04.02

  Reported2020.04.02

  Sensorion reports full-year 2019 results[3]Sensorion公布2019全年业绩finanznachrichten.de

  Sensorion announced its full-year 2019 financial results and provided a business update and outlook for 2020.

Read more

1. 1Sensorion (France) - Wikidatawikidata.org
2. 2Sensorion 将 GJB2 基因治疗靶点纳入开发组合finanznachrichten.de
3. 3Sensorion公布2019全年业绩finanznachrichten.de